post-add

Articles for Regulatory

IRGMA Applauds CDSCO’s New Guidelines, Calls For Strict Enforcement

The guidelines outlined the roles and responsibilities of the CDSCO’s Zonal, Sub-zonal, and Port offices and were released on September 12, marking the first update since 2011

Read More
Biocon Biologics Secures US Entry Date For Bmab 1200, A Stelara Biosimilar

Under the agreement, Biocon Biologics is licensed to launch Bmab 1200 in the United States, scheduled for February 2025, subject to approval by the U.S. FDA

Read More
No Development Without Research

For India and Indian companies to fulfil their enormous promise, a greater outlay towards research is paramount

Read More
Interim Budget Generates Serious Questions From India's FinMin

The shortest budget, very high on rhetoric, throws up serious questions which the discerning public demands answers, writes JK Dadoo

Read More
Innovative Optical Technology Receives Second Patent Boost In India

This additional patent solidifies and augments the original invention, unveiling unique features with the potential to enhance precision and productivity across various applications

Read More
Zydus Lifesciences Receives USFDA Nod For Generic Gabapentin Tablets

The company received final approval for manufacturing and marketing Gabapentin tablets in 300 mg and 600 mg strengths, making it the first to receive such approval

Read More
Alembic Pharmaceuticals Gets USFDA Approvals For Eight Drug Applications

The approvals include five final approvals for medications such as Selexipag Tablets (multiple strengths), Dapsone gel (7.5 per cent), Fluorouracil Injection USP 5g/100mL (50 mg/mL), Carmustine for Injection USP 100 mg/vial, and Acyclovir Cream (5 per cent)

Read More
Lupin Receives FDA Approval For Generic Equivalent Of Alrex Ophthalmic Suspension

This approval positions Lupin to market a generic equivalent to the reference listed drug (RLD) Alrex Ophthalmic Suspension, 0.2 per cent, produced by Bausch & Lomb

Read More

Subscribe to our newsletter to get updates on our latest news